![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
|
|
|
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Massimo G Colombo1, Ola Weiland2, Daniel E Cohen3, Jean-Francois DuFour4, Hendrik Reynaert5, Moisés Diago6, Erica Villa7, Adrian Streinu-Cercel8, Wangang Xie3, Jeff rey V Enejosa3, Eoin Coakley3,
Roger Trinh3, Thomas Podsadecki3
1Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 2Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; 3AbbVie Inc., North Chicago, Illinois, United States; 4Inselspital Bern, Bern, Switzerland;
5Universitair Ziekenhuis Brussels, Brussels, Belgium; 6Hospital Quiron de Valencia, Valencia, Spain; 7AOU Policlinico di Modena, Modena, Italy; 8Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania
![AASLD1.gif](../images/120114/120114-4/AASLD1.gif)
![AASLD2.gif](../images/120114/120114-4/AASLD2.gif)
![AASLD3.gif](../images/120114/120114-4/AASLD3.gif)
![AASLD4.gif](../images/120114/120114-4/AASLD4.gif)
![AASLD5.gif](../images/120114/120114-4/AASLD5.gif)
![AASLD6.gif](../images/120114/120114-4/AASLD6.gif)
![AASLD7.gif](../images/120114/120114-4/AASLD7.gif)
![AASLD8.gif](../images/120114/120114-4/AASLD8.gif)
![AASLD9.gif](../images/120114/120114-4/AASLD9.gif)
![AASLD10.gif](../images/120114/120114-4/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|